DexCom, Inc. (DXCM) Just Reaches 52-Week High?

July 12, 2018 - By Paula Hilliard

DexCom, Inc. (NASDAQ:DXCM) Logo

Investors sentiment increased to 1.15 in 2018 Q1. Its up 0.42, from 0.73 in 2017Q4. It improved, as 32 investors sold DexCom, Inc. shares while 71 reduced holdings. 45 funds opened positions while 73 raised stakes. 98.26 million shares or 0.86% less from 99.11 million shares in 2017Q4 were reported.
Sei Invests Co reported 0.03% in DexCom, Inc. (NASDAQ:DXCM). Fmr Limited Liability Corp stated it has 7.34M shares. Legal General Gp Public Ltd Company accumulated 44,982 shares or 0% of the stock. 8 are owned by Tci Wealth Advsr Inc. Marco Investment Limited Company invested in 3,500 shares or 0.04% of the stock. Stephens Gru Limited Liability Corp holds 0.51% or 317,460 shares in its portfolio. Cubist Systematic Strategies Ltd Liability, a Connecticut-based fund reported 1,000 shares. Federated Invsts Pa has invested 0.05% in DexCom, Inc. (NASDAQ:DXCM). Domini Impact Invs Limited Liability Corp stated it has 5.24% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Moreover, Lockheed Martin Inv Mngmt has 0.02% invested in DexCom, Inc. (NASDAQ:DXCM) for 7,780 shares. Fred Alger Mgmt owns 848,585 shares or 0.29% of their US portfolio. Northern Corp has invested 0.01% in DexCom, Inc. (NASDAQ:DXCM). Swiss Bancorporation stated it has 150,800 shares or 0.01% of all its holdings. Greenleaf invested in 167 shares. Daiwa Securities Grp holds 0.03% or 47,871 shares.

Since January 16, 2018, it had 0 buys, and 19 selling transactions for $21.60 million activity. MOY JEFFREY sold $5.47M worth of stock. SAYER KEVIN R had sold 17,245 shares worth $1.45M on Wednesday, May 9. TOPOL ERIC sold $2.00M worth of stock or 20,000 shares. DOUBLEDAY RICHARD had sold 1,635 shares worth $89,384 on Tuesday, January 23. SKYLER JAY S had sold 30,000 shares worth $2.64 million. 13,168 DexCom, Inc. (NASDAQ:DXCM) shares with value of $1.12 million were sold by Leach Jacob Steven.

The stock of DexCom, Inc. (NASDAQ:DXCM) hit a new 52-week high and has $107.76 target or 4.00 % above today’s $103.62 share price. The 8 months bullish chart indicates low risk for the $9.13 billion company. The 1-year high was reported on Jul, 12 by If the $107.76 price target is reached, the company will be worth $365.08M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.89% or $0.91 during the last trading session, reaching $103.62. About 114,116 shares traded. DexCom, Inc. (NASDAQ:DXCM) has risen 27.26% since July 12, 2017 and is uptrending. It has outperformed by 14.69% the S&P500.

Analysts await DexCom, Inc. (NASDAQ:DXCM) to report earnings on August, 7. They expect $-0.20 EPS, down 25.00 % or $0.04 from last year’s $-0.16 per share. After $-0.32 actual EPS reported by DexCom, Inc. for the previous quarter, Wall Street now forecasts -37.50 % EPS growth.

DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage

Among 13 analysts covering Dexcom (NASDAQ:DXCM), 10 have Buy rating, 1 Sell and 2 Hold. Therefore 77% are positive. Dexcom has $11500 highest and $57 lowest target. $79.91’s average target is -22.88% below currents $103.62 stock price. Dexcom had 19 analyst reports since January 17, 2018 according to SRatingsIntel. As per Wednesday, March 28, the company rating was maintained by Cowen & Co. The rating was upgraded by J.P. Morgan to “Buy” on Friday, June 8. On Thursday, May 3 the stock rating was maintained by Canaccord Genuity with “Buy”. The company was maintained on Thursday, May 3 by BMO Capital Markets. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Buy” rating by Cowen & Co on Wednesday, April 11. On Monday, July 2 the stock rating was upgraded by Raymond James to “Outperform”. The stock of DexCom, Inc. (NASDAQ:DXCM) has “Buy” rating given on Monday, April 9 by Stephens. On Friday, June 8 the stock rating was upgraded by JP Morgan to “Overweight”. The rating was maintained by BMO Capital Markets with “Buy” on Wednesday, March 28. The firm has “Outperform” rating given on Friday, March 23 by Robert W. Baird.

More notable recent DexCom, Inc. (NASDAQ:DXCM) news were published by: which released: “DexCom And The Missing Connection Between Stock Price And Fundamental Business” on July 09, 2018, also with their article: “Consolidated Research: 2018 Summary Expectations for Humana, DexCom, Royal Dutch Shell, First Connecticut …” published on June 14, 2018, published: “3 Top Growth Stocks to Buy in July” on July 11, 2018. More interesting news about DexCom, Inc. (NASDAQ:DXCM) were released by: and their article: “Big News Sends Tandem Diabetes Soaring 10.2% Today” published on June 22, 2018 as well as‘s news article titled: “Benzinga’s Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial” with publication date: July 12, 2018.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company has market cap of $9.13 billion. The firm offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. It currently has negative earnings. The Company’s products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

DexCom, Inc. (NASDAQ:DXCM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: